Actinogen Medical Limited released its earnings results on Feb 25, 2024. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.004.

Q: Is Actinogen Medical Limited overvalued?

According to Wall Street analysts Actinogen Medical Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: What happened to Actinogen Medical Limited’s price movement after its last earnings report?

Actinogen Medical Limited reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

0 Followers

3AC Stock Chart & Stats

Advanced Chart >

Day’s Range€0 - €0

52-Week Range<€0.01 - €0.03

Previous Close€0.02

Volume100.00

Average Volume (3M)100.05K

Market Cap

€44.39M

Enterprise Value€34.43M

Total Cash (Recent Filing)AU$16.37M

Total Debt (Recent Filing)AU$165.27K

Price to Earnings (P/E)N/A

Beta1.45

Next Earnings

Aug 28, 2024

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding2,326,920,711

10 Day Avg. Volume0

30 Day Avg. Volume100,050

Standard DeviationN/A

R-SquaredN/A

AlphaN/A

Financial Highlights & Ratios

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Actinogen Medical Limited News

PremiumCompany Announcements

Actinogen Medical Seeks Quotation for New Shares

12m ago

PremiumCompany Announcements

Actinogen Medical Aims to Raise $8.9 Million

1d ago

PremiumCompany Announcements

Actinogen Medical Launches New Share Offer

1d ago

PremiumCompany Announcements

Actinogen Medical Ramps Up $8.9M for Alzheimer’s Trial

5d ago

PremiumCompany Announcements

Actinogen Medical Awaits Fundraising News

7d ago

PremiumCompany Announcements

Actinogen Medical Advances Cognitive Treatment Trial

16d ago

PremiumCompany Announcements

Actinogen Medical Launches Alzheimer’s Trial

23d ago

PremiumCompany Announcements

Actinogen Medical Executes Share Buy-Back

23d ago

See More ATGGF News >

Financials

Annual

Income Statement >

3AC FAQ

What was Actinogen Medical Limited’s price range in the past 12 months?

Actinogen Medical Limited lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.

What is Actinogen Medical Limited’s market cap?

Currently, no data Available

When is Actinogen Medical Limited’s upcoming earnings report date?

Actinogen Medical Limited’s upcoming earnings report date is Aug 28, 2024 which is in 112 days.

How were Actinogen Medical Limited’s earnings last quarter?

Actinogen Medical Limited released its earnings results on Feb 25, 2024. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.004.

Is Actinogen Medical Limited overvalued?

According to Wall Street analysts Actinogen Medical Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Actinogen Medical Limited pay dividends?

Actinogen Medical Limited does not currently pay dividends.

What is Actinogen Medical Limited’s EPS estimate?

Actinogen Medical Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Actinogen Medical Limited have?

Currently, no data Available

What happened to Actinogen Medical Limited’s price movement after its last earnings report?

Actinogen Medical Limited reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Actinogen Medical Limited?

Currently, no hedge funds are holding shares in DE:3AC

---

Actinogen Medical Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

-102.54%

Trailing 12-Months

Asset Growth

-20.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Actinogen Medical Limited

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological and metabolic diseases. Geographically, it operates and derives revenue from Australia.

---

3AC Stock 12 Months Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","-1":"-€1","-0.5":"-€0.5","0.5":"€0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2022","6":"Dec<br/>2022","9":"Mar<br/>2023","12":"May<br/>2023","25":"May<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.024,0.022153846153846156,0.020307692307692308,0.018461538461538463,0.016615384615384615,0.01476923076923077,0.012923076923076924,0.011076923076923078,0.009230769230769232,0.007384615384615385,0.005538461538461541,0.0036923076923076927,0.001846153846153848,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.024,0.022153846153846156,0.020307692307692308,0.018461538461538463,0.016615384615384615,0.01476923076923077,0.012923076923076924,0.011076923076923078,0.009230769230769232,0.007384615384615385,0.005538461538461541,0.0036923076923076927,0.001846153846153848,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.024,0.022153846153846156,0.020307692307692308,0.018461538461538463,0.016615384615384615,0.01476923076923077,0.012923076923076924,0.011076923076923078,0.009230769230769232,0.007384615384615385,0.005538461538461541,0.0036923076923076927,0.001846153846153848,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.03,"date":1654041600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.02,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.027,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.034,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.043,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.069,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.057,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.048,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.045,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.038,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.027,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.024,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.024,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >